Need a Health professional?

Shreyaansh Lifesciences, Jaipur. India

Atezolizumab Injection 1200 mg
Atezolizumab injection is used alone to help prevent non-small cell lung cancer (NSCLC) from coming back in patients whose tumor has been removed by surgery and who have received other cancer medicines

Atezolizumab Injection was approved for medical use in the United States in 2016. It is on the World Health Organization’s List of Essential Medicines.

Atezolizumab Injection Available Price In India UK Saudi Arabia

Atezolizumab Injection

  • Packaging – Glass Bottle Single Use Vial
  • Strength – 1200 mg
  • Brand Name Available – Tecentriq
  • Company: Roche
  • Current indications: urothelial carcinoma; non-small cell lung cancer

What is Atezolizumab used for?

  • Atezolizumab injection is used alone to help prevent non-small cell lung cancer (NSCLC) from coming back in patients whose tumor has been removed by surgery and who have received other cancer medicines (eg, platinum). It is given to patients who have stage 2 to stage 3A NSCLC and whose tumors express PD-L1.
Disclaimer

All Trademarks and Brands that appear on website belong to their respective owners and Ikris Pharma Network does not lay and claim on them we only provide Information. We are NOT ONLINE store and We do not sell Narcotics and Sedatives. Iron Sucrose is a pharmaceutical drug that legally requires a medical prescription to be dispensed. Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.

Get Access To Atezolizumab Injection 1200 mg

Shreyaansh Lifesciences, Jaipur. India

Shreyaansh Lifesciences is registered in Jaipur, India. Registration Number : 08AEEFS9350K1ZI under GST Act. 
Branch Offices in India : Jaipur | New Delhi

SF-72-73 2ND FLOOR, Jaipur Electronic Market, Ridhi Sidhi Choraha, Jaipur, Rajasthan, 302018.

+91 99292 77766

Facts of Medicines

Atezolizumab Injection 1200 mg

SUPPLIED/STORAGE AND HANDLING:

Atezolizumab Injection should be stored at 2 °C to 8 °C (36 °F to 46 °F). Do not freeze. Do not shake. Do not use beyond the expiration date.

Atezolizumab Injection SIDE EFFECTS

The most commonly reported abciximab side effects include bleeding, hypotension, back pain, nausea, chest pain, vomiting, headache, bradycardia, abdominal pain, puncture site pain, peripheral edema.

Atezolizumab Injection DOSAGE

Administer 1200 mg as an intravenous infusion over 60 minutes every 3 weeks. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.
Injection: 1200 mg/20 mL (60 mg/mL) solution in a single-dose vial.

WARNINGS AND PRECAUTIONS

  • Genetic testing should be indicated in order to detect whether a person is at higher risk of developing hypersensitivity.
  • Atezolizumab may not be added as a single agent when antiretroviral regimens are changed because of loss of the virologic response.
  • Patients with liver disease should be watchful and cautious in order to Atezolizumab because it can aggravate the condition.
  • In patients with Atezolizumab, conditions like immune reconstitution inflammatory syndrome, a change in body fat as well as an increased risk of heart attack may occur.
  • Atezolizumab is not recommended for use in infants who are under 3 months of age.
  • Cases like lactic acidosis and severe hepatomegaly with steatosis occurred with the use of nucleoside analogues.
  • Sometimes serious hypersensitivity reactions have been associated with Atezolizumab.

FAQs – Medicine Questions

Atezolizumab Injection 1200 mg
Is atezolizumab approved by FDA?
On October 15, 2021, the FDA approved atezolizumab (brand name Tecentriq) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer whose tumors have PD-L1 expression on more than 1% of tumor cells, as determined by an FDA-approved test.
When was atezolizumab approved by FDA?
FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer. On October 15, 2021, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.)
What is atezolizumab approved for?

 Tecentriq (atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for use in the treatment of urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), heptatocellular carcinoma and melanoma.

Where can I buy Atezolizumab Injection?

You can buy Atezolizumab Injection from any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.

The buyer should check the existing law in their home country before importing the product.

What is the procedure to buy Atezolizumab Injection?

Patients can simply fill the order form or can send mail at info@treatmentoptions4u.com. Patients can also send WhatsApp messages to +91 98738 10020. We will reply ASAP with the details of the Atezolizumab Injection as well as procurement procedure.

Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.

What is Tecentriq used for?
TECENTRIQ is a prescription medicine used to treat adults with: A type of bladder and urinary tract cancer called urothelial carcinoma.

NEWS / UPDATES

  1. Roche, Electronic Medicines Compendium (EMC) [Revised on Sep 2021] [Accessed on 27th Nov 2021],  https://www.medicines.org.uk/emc/files/pil.8442.pdf
  2. Genentech Inc, US Food and Drug Administration [Revised on Oct 2021] [Accessed on 27th Nov 2021],  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s028lbl.pdf
  3. Anton Wellstein, Giuseppe Giaccone, Michael B. Atkins, and Edward A. Sausville, Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules, Goodman & Gilman’s Pharmacological Basis of Therapeutics, 13th Edition, 2018, 1203-1236.
  4. Douglas F. Lake and Adrienne D. Briggs, Immunopharmacology, Lange’s Basic & Clinical Pharmacology, 14th Edition, 2018, 977-1002.